Bevacizumab for Retinopathy of Prematurity: 2-Year Neurodevelopmental Follow-up

Conclusion Bevacizumab therapy for ROP did not affect survival and neurodevelopment of extremely preterm infants.
Key Points
[...] Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.Article in Thieme eJournals: Table of contents  |  Abstract  |  Full text

Source: American Journal of Perinatology - May 22, 2020 Category: Perinatology & Neonatology Authors: Zayek, Michael Parker, Kaitlyn Rydzewska, Monika Rifai, Aref Bhat, Ramachandra Eyal, Fabien Tags: Original Article Source Type: research